Skip to main content

Cytokine Fusion Protein Treatment

  • Conference paper

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 160))

Abstract

Mice suffering from melanoma can be cured by treatment with a recombinant antibody-lymphotoxin-a fusion protein. In order to characterize the involvement of T cells in this syngeneic tumor model, the T cell receptor repertoire was analyzed both quantitatively and qualitatively. In this connection, quantitative analysis of the T cell receptors displayed only a modest overexpression in some of the variable beta chain families over the course of therapy. Clonotypic mapping, however, revealed a marked increase in the number of clonally expanded T cells among the tumor-infiltrating T cells, suggesting a specific activation.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Becker JC, Pancook JD, Gillies SD, Furukawa K, Reisfeld RA (1996) T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med 183:2361–2366.

    Article  PubMed  CAS  Google Scholar 

  • De Togni P, Goellner J, Ruddle NH, Streeter PR, Fick A, Mariathasan S, Smith SC, Carlson R, Shornick LP, Strauss-Schoenberger J (1994) Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 264:703–707.

    Article  PubMed  Google Scholar 

  • Gillies SD, Young D, Lo KM, Foley SF, Reisfeld RA (1991) Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD2 antibody Hybridoma 10:347–356.

    Google Scholar 

  • Kirkin AF, Dzhandzhugazyan K, Zeuthen J (1998) Melanoma-associated antigens recognizedby cytotoxic T lymphocytes. APMIS 106:665–679.

    Article  PubMed  CAS  Google Scholar 

  • Koni PA, Sacca R, Lawton P, Browning JL, Ruddle NH, Flavell RA (1997) Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beta-deficient mice. Immunity 6:491–500.

    Article  PubMed  CAS  Google Scholar 

  • Reisfeld RA, Gillies SD, Mendelsohn J, Varki NM, Becker JC (1996) Involvement of B lymphocytes in the growth inhibition of human pulmonary melanoma metastases in athymic nu/nu mice by an antibody-lymphotoxin fusion protein. Cancer Res 56:1707–1712.

    PubMed  CAS  Google Scholar 

  • Rennert PD, Browning JL, Mebius R, Mackay F, Hochman PS (1996) Surface lymphotoxin alpha/beta complex is required for the development of peripheral lymphoid organs. J Exp Med 184:1999–2006.

    Article  PubMed  CAS  Google Scholar 

  • Ruddle NH (1999) Lymphoid neo-organogenesis: lymphotoxin’s role in inflammation and development. Immunol Res 19:119–125.

    Article  PubMed  CAS  Google Scholar 

  • Sabzevari H, Gillies SD, Mueller BM, Pancook JD, Reisfeld RA (1994) A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci USA 91: 9626–9630.

    Article  PubMed  CAS  Google Scholar 

  • Staveley-O’Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D, Levitsky H (1998) Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA 95:1178–1183.

    Article  PubMed  Google Scholar 

  • thor Straten P, Guldberg P, Seremet T, Reisfeld RA, Zeuthen J, Becker JC (1998) Activation of preexisting T cell clones by targeted interleukin 2 therapy. Proc Natl Acad Sci USA 95:8785–8790.

    Article  CAS  Google Scholar 

  • thor Straten P, Guldberg P, Gronbaek K, Hansen MR, Kirkin AF, Seremet T, Zeuthen J, Becker JC (1999) In situ T cell responses against melanoma comprise high numbers of locally expanded T cell clonotypes. J Immunol 163:443–447.

    PubMed  CAS  Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Schrama, D., >thor Straten, P., Bröcker, EB., Reisfeld, R.A., Becker, J.C. (2002). Cytokine Fusion Protein Treatment. In: Dummer, R., Nestle, F.O., Burg, G. (eds) Cancers of the Skin. Recent Results in Cancer Research, vol 160. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59410-6_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-59410-6_22

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-63969-2

  • Online ISBN: 978-3-642-59410-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics